期刊文献+

PPAR γ在子宫内膜癌中的研究进展 被引量:5

Research Progress of PPAR γ in Endometrial Cancer
下载PDF
导出
摘要 过氧化氢酶增殖物激活受体(peroxisome proliferator-activated receptors,PPARs)是细胞核雌激素受体家族成员,包括PPARα、β/δ和γ。PPARγ参与脂肪与碳水化合物的代谢过程,因与多种代谢性疾病及肿瘤形成密切相关而成为研究的热点。PPARγ是配体依赖的转录因子,与子宫内膜癌细胞的增殖、侵袭和转移有关,但在子宫内膜癌中的研究较少,且具体作用机制尚不明确。综述PPARγ在子宫内膜癌相关的研究进展,旨在探讨PPARγ参与子宫内膜癌发生发展的机制,为临床后续的抗肿瘤治疗提供理论依据。 Peroxisome proliferator-activated receptors(PPARs) are members of nuclear-hormone-receptor family which including PPARα, β/δ and γ. As a hotspot of researches in recent years, PPAR γ is closely related to a variety of metabolic diseases and tumors, which plays an important role in metabolism of lipid and carbohydrate. It functions as ligand-dependent transcription factors, connected with the proliferation,invasion and migration of endometrial cancer cells. The role of PPAR γ in tumorigenesis of endometrial cancer remains unclear. In this article, we reviewed studies progress of PPAR γ in endometrial cancer, discussing the role of PPAR γ in tumorigenesis of endometrial cancer and potential mechanism underlying endometrial cancer development and furthering propose theoretical basis for anti-tumor therapy.
出处 《国际妇产科学杂志》 CAS 2018年第1期80-84,共5页 Journal of International Obstetrics and Gynecology
基金 福建省自然科学基金(2016J01428 2017J01233)
关键词 PPAR γ 子宫内膜肿瘤 维甲类X受体 信号传导 过氧化氢酶增殖物激活受体-γ激动剂 PPAR gamma Endometrial neoplasms Retinoid X receptors Signal transduction Peroxisome proliferator-activated γ agonist
  • 相关文献

参考文献2

二级参考文献36

  • 1Boll D, Karim-Kos HE, Verhoeven RH, et al. Increased incidence and improved survival in endometrioid endometrial cancer diag- nosed since 1989 in The Netherlands: a population based study[J]. EurJ Obstet Gynecol Reprod Biol, 2013, 166(2):209-214.
  • 2Wang Y, Zhu Y, Zhang L, et al. Insulin promotes proliferation, sur- vival, and invasion in endometrial carcinoma by activating the MEK/ERKpathway[J]. Cancer Lett, 2012, 322(2):223-231.
  • 3Yuan H, Kopelovich L, Yin Y, et al. Drug-targeted inhibition of peroxisome proliferator-activated receptor-gamma enhances the chemopreventive effect of anti--estrogen therapy[J]. Oncotarget, 2012, 3(3):345-356.
  • 4Issemann I, Green S. Activation of a member of the steroid hor mone receptor superfamily by peroxisome proliferators[J]. Nature, 1990, 347 (6294) :645-650.
  • 5Ota K, Ito K, Suzuki T, et al. Peroxisome proliferator--activated re- ceptor ganmaa and growth inhibition by its ligands in uterine endo- metriai carcinoma[J]. Clin Cancer Res, 2006, 12(14 Pt 1):4200-4208.
  • 6Holland CM, Saidi SA, Evans AL, et al. Transcriptome analysis of endometrial cancer identifies peroxisome proliferator-activated re- ceptors as potential therapeutic targets[J]. Mol Cancer Ther, 2004, 3 (8):993-1001.
  • 7Nickkho-Amiry M, McVey R, Holland C. Peroxisome prolifera- tor-activated receptors modulate proliferation and angiogenesis in hmnan endometrial carcinoma[J]. Mol Cancer Res, 2012, 10(3): 441-453.
  • 8Stoian SC, Simionescu C, Mrg ritescu C, et al. Endometrial carcino- mas: correlation between ER, PR, Ki67 status and histopathological prognostic parameters[J]. Rom J Morphol Embryol, 2011, 52(2): 631-636.
  • 9Ito K, Utsunomiya H, Yaegashi N, et al. Biological roles of estrogen and progesterone in human endometrial carcinoma--new develop- ments in potential endocrine therapy for endometrial cancer[J]. En- docrJ, 2007, 54,(5):667-679.
  • 10Hu K, Zhong G, He F. Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma[J]. Int j Gynecol Cancer, 2005, 15(3):537-541.

共引文献9

同被引文献31

引证文献5

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部